Health ❯ Healthcare ❯ Pharmaceuticals

Weight Loss

GLP-1 Drugs GLP-1 Medications Wegovy Mounjaro Obesity Treatments Semaglutide Obesity Treatment Orforglipron Clinical Trials GLP-1 Receptor Agonists

Wegovy Pill Fuels Massive Private Demand in UK as Supply Questions Grow

High preorders point to broader patient uptake with a real risk that manufacturing may not keep pace.

Wearable Data Show People Move Less After Starting GLP‑1 Weight‑Loss Drugs

MHRA Approves Wegovy Daily Pill for Weight Loss in UK

AstraZeneca’s Oral GLP‑1 Elecoglipron Delivers Strong Phase 2 Weight and Blood‑Sugar Results

Employers and Insurers Pull Back Coverage for GLP‑1 Weight‑Loss Drugs

Eli Lilly Spends $3.8 Billion to Build Vaccine Business

UAE Becomes First Country Outside U.S. to Offer Wegovy Pill

CVS Caremark Restores Zepbound and Adds Lilly’s Foundayo to Standard Formularies

Lilly’s Triple‑Agonist Retatrutide Produces Surgery‑Level Weight Loss in Phase 3 Trial

CHMP Recommends Adding Oral Wegovy Tablets to EU Approval

New Data Link GLP-1 Weight-Loss Drugs to Fewer Sick Days and Lower Disease Risks

New Trials Show Daily Pills Can Help Maintain Weight Loss After GLP-1 Injections

Novo Nordisk Lifts Outlook After Wegovy Pill Fuels Q1 Beat

CMS Pauses Medicare GLP-1 Pilot After Insurers Balk, Sets 2026–27 Bridge

Kailera Leaps 62% in Nasdaq Debut After $625 Million IPO

UK Regulators Approve Single-Dose 7.2mg Wegovy Pen for Weekly Use

India’s Generic Semaglutide Wave Eats Into Mounjaro’s Lead as Novo Holds Share

Amazon Pharmacy Launches Same-Day Delivery for Lilly’s Foundayo Weight-Loss Pill

FDA Clears Eli Lilly’s Foundayo Oral GLP-1 for Weight Loss, With U.S. Launch Set for April 6

Brazil Overhauls Obesity Drug Guidance as FDA Approves Lilly’s Daily Pill